Literature DB >> 30819968

Duration of Initial Empirical Antibiotic Therapy and Outcomes in Very Low Birth Weight Infants.

Joseph Y Ting1,2, Ashley Roberts1, Rebecca Sherlock3, Cecil Ojah4, Zenon Cieslak5, Michael Dunn6, Keith Barrington7, Eugene W Yoon8, Prakesh S Shah8,9.   

Abstract

: media-1vid110.1542/5984244681001PEDS-VA_2018-2286Video Abstract
BACKGROUND: Overuse of antibiotics can facilitate antibiotic resistance and is associated with adverse neonatal outcomes. We studied the association between duration of antibiotic therapy and short-term outcomes of very low birth weight (VLBW) (<1500 g) infants without culture-proven sepsis.
METHODS: We included VLBW infants admitted to NICUs in the Canadian Neonatal Network between 2010-2016 who were exposed to antibiotics but did not have culture-proven sepsis in the first week. Antibiotic exposure was calculated as the number of days an infant received antibiotics in the first week of life. Composite primary outcome was defined as mortality or any major morbidity (severe neurologic injury, retinopathy of prematurity, necrotizing enterocolitis, chronic lung disease, or hospital-acquired infection).
RESULTS: Of the 14 207 included infants, 21% (n = 2950), 38% (n = 5401), and 41% (n = 5856) received 0, 1 to 3, and 4 to 7 days of antibiotics, respectively. Antibiotic exposure for 4 to 7 days was associated with higher odds of the composite outcome (adjusted odds ratio 1.24; 95% confidence interval [CI] 1.09-1.41). Each additional day of antibiotic use was associated with 4.7% (95% CI 2.6%-6.8%) increased odds of composite outcome and 7.3% (95% CI 3.3%-11.4%) increased odds in VLBW infants at low risk of early-onset sepsis (born via cesarean delivery, without labor and without chorioamnionitis).
CONCLUSIONS: Prolonged empirical antibiotic exposure within the first week after birth in VLBW infants is associated with increased odds of the composite outcome. This practice is a potential target for antimicrobial stewardship.
Copyright © 2019 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30819968     DOI: 10.1542/peds.2018-2286

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  23 in total

Review 1.  Malnutrition, poor post-natal growth, intestinal dysbiosis and the developing lung.

Authors:  Mark A Underwood; Satyan Lakshminrusimha; Robin H Steinhorn; Stephen Wedgwood
Journal:  J Perinatol       Date:  2020-10-14       Impact factor: 2.521

2.  Impact of Early-Onset Sepsis and Antibiotic Use on Death or Survival with Neurodevelopmental Impairment at 2 Years of Age among Extremely Preterm Infants.

Authors:  Sagori Mukhopadhyay; Karen M Puopolo; Nellie I Hansen; Scott A Lorch; Sara B DeMauro; Rachel G Greenberg; C Michael Cotten; Pablo J Sánchez; Edward F Bell; Eric C Eichenwald; Barbara J Stoll
Journal:  J Pediatr       Date:  2020-06       Impact factor: 4.406

Review 3.  Spontaneous intestinal perforation (SIP) will soon become the most common form of surgical bowel disease in the extremely low birth weight (ELBW) infant.

Authors:  Jonathan R Swanson; Amy Hair; Reese H Clark; Phillip V Gordon
Journal:  J Perinatol       Date:  2022-02-17       Impact factor: 2.521

4.  [Effect of improvement in antibiotic use strategy on the short-term clinical outcome of preterm infants with a gestational age of <35 weeks].

Authors:  Mei-Yan Chu; Ming-Jie Wang; Jin Lin; Ge Yang; Ying Ding; Zheng-Chang Liao; Chuan-Ding Cao; Shao-Jie Yue
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-05-15

5.  Antibiotic spectrum index: A new tool comparing antibiotic use in three NICUs.

Authors:  Brynne A Sullivan; Aneesha Panda; Aaron Wallman-Stokes; Rakesh Sahni; Karen D Fairchild; Jason G Newland; Christopher C McPherson; Zachary A Vesoulis
Journal:  Infect Control Hosp Epidemiol       Date:  2021-11-23       Impact factor: 6.520

6.  Influence of Patient Characteristics on Antibiotic Use Rates Among Preterm Infants.

Authors:  Dustin D Flannery; Sagori Mukhopadhyay; Erik A Jensen; Jeffrey S Gerber; Molly R Passarella; Kevin Dysart; Zubair H Aghai; Jay Greenspan; Karen M Puopolo
Journal:  J Pediatric Infect Dis Soc       Date:  2021-03-26       Impact factor: 3.164

7.  Early Use of Antibiotics Is Associated with a Lower Incidence of Necrotizing Enterocolitis in Preterm, Very Low Birth Weight Infants: The NEOMUNE-NeoNutriNet Cohort Study.

Authors:  Yanqi Li; René Liang Shen; Adejumoke I Ayede; Janet Berrington; Frank H Bloomfield; Olubunmi O Busari; Barbara E Cormack; Nicholas D Embleton; Johannes B van Goudoever; Gorm Greisen; Zhongqian He; Yan Huang; Xiaodong Li; Hung-Chih Lin; Jiaping Mei; Paula P Meier; Chuan Nie; Aloka L Patel; Per T Sangild; Thomas Skeath; Karen Simmer; Signe Uhlenfeldt; Marita de Waard; Sufen Ye; Xuqiang Ye; Chunyi Zhang; Yanna Zhu; Ping Zhou
Journal:  J Pediatr       Date:  2020-06-14       Impact factor: 4.406

8.  Association Between Antibiotic Overexposure and Adverse Outcomes in Very-Low-Birth-Weight Infants Without Culture-Proven Sepsis or Necrotizing Enterocolitis: A Multicenter Prospective Study.

Authors:  Shanshan Hou; Yanqiu Wu; Yangyang Cao; Jinghui Zhang; Zhijie Liu; Cheng Guo; Yao Chen; Xuemei Sun; Min Li; Yanling Gao; Guoying Zhao; Shiping Niu; Zhiyuan Zhou; Yu Wang; Zhenying Yang; Lei Huang; Chengyuan Zhang; Tong Chen; Xia Li; Yongfeng Zhang; Peng Zhao; Meirong Bi; Riming Zhao; Yonghui Yu; Xinfeng Zhao
Journal:  Indian J Pediatr       Date:  2022-03-14       Impact factor: 5.319

9.  Each Additional Day of Antibiotics Is Associated With Lower Gut Anaerobes in Neonatal Intensive Care Unit Patients.

Authors:  Ashley M Rooney; Kathryn Timberlake; Kevin A Brown; Saumya Bansal; Christopher Tomlinson; Kyong-Soon Lee; Michelle Science; Bryan Coburn
Journal:  Clin Infect Dis       Date:  2020-06-10       Impact factor: 9.079

10.  Rates of Bronchopulmonary Dysplasia Following Implementation of a Novel Prevention Bundle.

Authors:  Maria Fe B Villosis; Karine Barseghyan; Ma Teresa Ambat; Kambiz K Rezaie; David Braun
Journal:  JAMA Netw Open       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.